<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04198506</url>
  </required_header>
  <id_info>
    <org_study_id>KKS-256</org_study_id>
    <secondary_id>2019-001770-29</secondary_id>
    <nct_id>NCT04198506</nct_id>
  </id_info>
  <brief_title>Viral Load Guided Immunosuppression After Lung Transplantation</brief_title>
  <acronym>VIGILung</acronym>
  <official_title>Viral Load Guided Immunosuppression After Lung Transplantation, an Open-label, Randomized, Controlled, Parallel-group, Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philipps University Marburg Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philipps University Marburg Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The VIGILung study is an open-label, randomized, multicenter trial in lung transplant&#xD;
      recipients to investigate the safety and efficacy of personalized immunosuppression guided by&#xD;
      DNA monitoring of Torque-Teno-Virus (TTV). The aim of the study is to investigate an&#xD;
      individual adaptation of the calcineurin inhibitor tacrolimus (tailored calcineurin inhibitor&#xD;
      dosing) by a non-invasive biomarker (TTV viral load in whole blood) compared to conventional&#xD;
      calcineurin inhibitor dosing. Indicator for toxicity will be the glomerular filtration rate&#xD;
      (GFR), which will be estimated using the CKD-EPI formula. 250 patients (age ≥ 18 years) with&#xD;
      21 to 42 days after de novo lung transplantation (bilateral or combined) will be screened as&#xD;
      possible subjects eligible for the study. N = 144 patients have to be randomized in two study&#xD;
      arms. In Arm 1 tacrolimus doses will be adapted according to the tacrolimus blood level&#xD;
      (conventional therapeutic drug monitoring - TDM) and additionally depending on TTV viral&#xD;
      load. In Arm 2 tacrolimus doses will be adapted according to TDM.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ΔGFR change of the glomerular filtration rate GFR</measure>
    <time_frame>Between randomization and 12 months thereafter</time_frame>
    <description>The primary efficacy endpoint ΔGFR is defined as the change of the glomerular filtration rate GFR between randomization and 12 months thereafter. GFR will be estimated using the CKD-EPI formula.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GFR (CKD-EPI)</measure>
    <time_frame>1 and 2 months after transplantation (screening visits) and 0, 3, 6, 9 and 12 months after randomization</time_frame>
    <description>Glomerular filtration rate (the Chronic Kidney Disease Epidemiology Collaboration - CKD-EPI) formula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GFR (Cystatin)</measure>
    <time_frame>At randomization and 12 months after randomization</time_frame>
    <description>Glomerular filtration rate (Cystatin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with biopsy-proven acute cellular rejection (grade A1 or higher)</measure>
    <time_frame>Between randomization and 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with an episode of biopsy-proven lymphocytic bronchitis (grade B1R or higher)</measure>
    <time_frame>Between randomization and 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with cytomegalovirus (CMV)-infection and number of CMV-disease episodes</measure>
    <time_frame>Between randomization and 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with community-acquired respiratory viral infection (CARV)</measure>
    <time_frame>Between randomization and 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with fungal and bacterial infections</measure>
    <time_frame>Between randomization and 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with any of the above mentioned infections</measure>
    <time_frame>Between randomization and 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with unscheduled or emergency hospitalizations</measure>
    <time_frame>Between randomization and 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with ICU admissions</measure>
    <time_frame>Between randomization and 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life (EQ-5D visual analog scale)</measure>
    <time_frame>1 and 2 months after transplantation (screening visits) and 0, 3, 6, 9 and 12 months after randomization</time_frame>
    <description>European Quality of Life 5 Dimensions - EQ-5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with new or progressive malignancy</measure>
    <time_frame>Between randomization and 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tacrolimus trough levels</measure>
    <time_frame>1 and 2 months after transplantation (screening visits) and 0, 3, 6, 9 and 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>daily tacrolimus dose [mg]</measure>
    <time_frame>1 and 2 months after transplantation (screening visits) and 0, 3, 6, 9 and 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with increased/unchanged/decreased (compared to previous visit) target trough levels of tacrolimus</measure>
    <time_frame>1 and 2 months after transplantation (screening visits) and 0, 3, 6, 9 and 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>exercise capacity measured by the percent predicted distance achieved in the 6-minute walk test (6-MWT)</measure>
    <time_frame>at randomization and 12 months thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4-Lymphocytes counts</measure>
    <time_frame>0, 6 and 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with presence of donor specific antibodies</measure>
    <time_frame>0, 6 and 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 in % baseline value</measure>
    <time_frame>1 and 2 months after transplantation (screening visits) and 0, 3, 6, 9 and 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of chronic lung allograft dysfunction</measure>
    <time_frame>Between randomization and 12 months thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgG-level</measure>
    <time_frame>0, 6 and 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with rescue immunotherapy (defined by the use of ATG, Rituximab, Alemtuzumab, plasma exchange, immunoadsorption)</measure>
    <time_frame>Between randomization and 12 months thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time from randomization to graft loss (defined as re-do transplantation or death)</measure>
    <time_frame>randomization until 12 months thereafter</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Transplantation Lung</condition>
  <arm_group>
    <arm_group_label>Tailored tacrolimus dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring - TDM) and additionally depending on TTV viral load.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional tacrolimus dosing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring - TDM).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tailored tacrolimus dosing</intervention_name>
    <description>Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring -TDM) and additionally depending on TTV viral load.</description>
    <arm_group_label>Tailored tacrolimus dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional tacrolimus dosing</intervention_name>
    <description>Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring - TDM).</description>
    <arm_group_label>Conventional tacrolimus dosing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. patients 21 to 42 days after primary de novo lung transplantation (bilateral including&#xD;
             combined)&#xD;
&#xD;
          2. age ≥ 18 years&#xD;
&#xD;
          3. tacrolimus based immunosuppression&#xD;
&#xD;
          4. written informed consent&#xD;
&#xD;
          5. detectable TTV load at randomization (&gt;2,7 log 10)&#xD;
&#xD;
          6. negative serum pregnancy test in women of childbearing potential.&#xD;
&#xD;
          7. women of childbearing capacity must agree to maintain highly effective methods of&#xD;
             contraception by practicing abstinence or by using at least two methods of birth&#xD;
             control from the date of consent through the end of the study. If abstinence is not&#xD;
             practiced, a combination of hormonal contraceptive (oral, injectable or implants) and&#xD;
             a barrier method (condom, diaphragm with a vaginal spermicidal agent) has to be used.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. patients after unilateral or re-do lung transplantation&#xD;
&#xD;
          2. history or high-risk of obstructive airway complications after lung transplantation&#xD;
&#xD;
          3. respiratory failure (need for oxygen therapy or ventilation at screening after lung&#xD;
             transplantation)&#xD;
&#xD;
          4. inability to undergo transbronchial biopsy&#xD;
&#xD;
          5. advanced kidney failure (GFR CKD-EPI &lt;30 ml/min/1.73m2 at inclusion and/or current&#xD;
             renal replacement therapy at inclusion or randomization&#xD;
&#xD;
          6. advanced liver cirrhosis (CHILD-Pugh Score C) after lung transplantation&#xD;
&#xD;
          7. fluctuating tacrolimus drug levels (less than 20% in target range after&#xD;
             transplantation)&#xD;
&#xD;
          8. symptoms of significant mental illness and with inability to cooperate or communicate&#xD;
             with the investigator.&#xD;
&#xD;
          9. unlikeliness to comply with the study requirements&#xD;
&#xD;
         10. HIV positivity&#xD;
&#xD;
         11. evidence of unsolved drug or alcohol addiction&#xD;
&#xD;
         12. breastfeeding women&#xD;
&#xD;
         13. simultaneous participation in other clinical trials if not permitted by the steering&#xD;
             committee&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Gottlieb, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Pneumologie OE 6870, Medizinische Hochschule Hannover (MHH)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jens Gottlieb, Prof. MD</last_name>
    <phone>+49 (0) 511-532-4601</phone>
    <email>gottlieb.jens@mh-hannover.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medizinische Universität Wien, Klinische Abteilung für Thoraxchirurgie</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Jaksch, MD</last_name>
      <phone>0043-1-40400-20513</phone>
      <email>peter.jaksch@meduniwien.ac.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Pneumologie OE 6870, Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Gottlieb, Prof. MD</last_name>
      <phone>+49 (0) 511-532-4601</phone>
      <email>gottlieb.jens@mh-hannover.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung transplantation</keyword>
  <keyword>dosing immunosuppression</keyword>
  <keyword>toxicity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All proposals of scientific question dealing with the data of the VIGLung-trial have to be approved and released by the steering committee of the trial.</ipd_description>
    <ipd_time_frame>data will be available Begin: one year after publication of results. End: maximum ten years after publication of results</ipd_time_frame>
    <ipd_access_criteria>Approval and release by the steering committee</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

